Supplementary Material for: Case report: ICI-induced bullous pemphigoid: Successful treatment with dupilumab while maintaining immunotherapy

Introduction: Immune checkpoint inhibitors (ICIs) represent a new class of antitumor agents in oncology. Their use has been associated with a specific safety profile, known as immune-related adverse events (irAEs), with dermatological toxicities being the most frequently encountered. Case report: We report the case of a bullous pemphigoid (BP) in a metastatic melanoma patient, treated with ipilimumab and nivolumab. This immune-mediated toxicity was controlled by using dupilumab as a steroid-sparing therapy, allowing the reintroduction of immunotherapy without relapse. Conclusion: This case illustrates the complexity of managing some dermatological irAEs and the need for better treatment strategies. Dupilumab is a promising agent for cutaneous irAEs, including ICI-BP. To our knowledge, our case is the first one in which a rechallenge with an ICI was attempted after a dupilumab treatment for an ICI-BP.